CYFRA 21-1 (Cytokeratin 19 Fragment), Serum
Cytokeratins, belonging to the intermediate filament protein family, are good markers in cancer diagnostics and management. The three most applied cytokeratin markers in cancer diagnostics and management are tissue polypeptide antigen (TPA), tissue polypeptide specific antigen (TPS), and CYFRA 21-1. TPA is a broad-spectrum test that measures cytokeratins 8, 18, and 19. TPS and CYFRA 21-1 assays are more specific and measure cytokeratin 18 and cytokeratin 19, respectively. CYFRA 21-1 is a new test measuring fragments of cytokeratin 19 in human blood. Fragments of cytokeratin-19 are frequently released into the blood of cancer patients. In fact, the presence of cytokeratin fragments in the serum of patients suffering from cancer would be linked to their release during the course of cellular death.
Since CYFRA 21-1 is specific to lung diseases, use of this test is specifically as a marker in tumor pathology, especially in lung cancer. The main utility for CYFRA 21-1 is monitoring the course of non-small cell lung cancer (NSCLC) and detection of recurrent disease after primary therapy. CYFRA 21-1 has a clear prognostic value in both early and late stages of NSCLC, and high serum levels indicate an advanced tumor stage and a poor prognosis. CYFRA 21-1 is a valuable marker in the prediction of the response to chemo therapies and radiation therapy in diverse cancers such as hepatic cancer or hepatic metastases, urological, gastrointestinal and gynecological cancers. Most recent studies have shown that CYFRA 21-1 is also elevated in colorectal adenoma, and could be used as a screening marker for diagnosis of colorectal adenoma; however, more study is needed. Furthermore, there are studies showing associations of the CYFRA 21-1 and that this marker can be used for diagnosis of bladder cancer.
- To monitor treatment and response to therapy for NSCLC
- Early prognostic information, particularly on tumor progression and metastasis
Increased in:
- Non-small cell lung cancer
- Colorectal adenoma
- Hepatic metastases
- Urological cancer
- Gastrointestinal
- Gynecological cancers
<3.3 ng/mL (For patients with benign lung diseases)
Serum, Plasma
Stability
- Ambient: 48 hours
- Refrigerated: 2 weeks
- Frozen: 2 months
- Scand J Clin Lab Invest Suppl. 1995;221:60-6. [PMID: 7544487]
- Br J Cancer. 2004 Jun 1;90(11):2097-105. [PMID: 15150567]
- J Clin Lab Anal. 2017 Feb 10. doi: 10.1002/jcla.22163. [PMID: 28186354]
- Clin Biochem. 2004 Jul;37(7):529-40. [PMID: 15234234]
- Anticancer Res. 1999 Jul-Aug;19(4A):2669-72. [PMID: 10470217]
- Clin Cancer Res. 2003 May;9(5):1728-33. [PMID: 12738727]
- Br J Cancer. 1994 Mar;69(3):525-8. [PMID: 7510117]
- J Med Assoc Thai. 2000 Apr;83(4):383-91. [PMID: 10808698]
- Tumour Biol. 2015 May;36(5):3137-45. [PMID: 25854170]